Controlled document PF-008A
PLEXUS SOLARIS Phase 2 Master Formula
Record identification
- Document ID
- PF-008A
- Document type
- Template
- Status
- Documented
- Source
- Standardisation & Production of SIRIAM Products
Overview
PF-008A
PRODUCT FORMULA CARD
SIRIAM PLEXUS SOLARIS DUO – PHASE 2 (INTEGRATION)
DOCUMENT CONTROL
Field
Product ID
Formula ID
Document
Product
Anatomical Region
Therapeutic Phase
Product Type
Standard Batch
Version
Status
Internal QR
| Value |
|---|
| SIR-PS-002 |
| MF-008 |
| PF-008A |
| PLEXUS SOLARIS DUO – Phase 2 |
| T5–T9 |
| Viscero-Autonomic Integration |
| Topical Magistral Cream |
| 100 g |
| 2.0 |
| 🔒 LOCKED |
| ☐ |
1. PRODUCT PURPOSE
Field
Clinical Objective
Anatomical Region
Primary Biological Target
Therapeutic Phase
Product Type
The magistral fiche defines Phase 2 as stabilisation with viscero-autonomic integration.
| Description |
|---|
| Neurovisceral stabilisation of the solar plexus |
| T5–T9 |
| Viscero-autonomic integration |
| Phase 2 – Integration |
| Topical Magistral Cream |
2. MASTER FORMULA
All ingredient quantities originate from the uploaded Phase 2 magistral fiche, with the agreed SQMS naming conventions.
| Code |
|---|
| Official Ingredient |
| Supplier |
| Master Qty |
| Unit |
| Phase |
| PC-001 |
| Lanette Cream FNA |
| Fagron |
| 67.00 |
| g |
| B |
| PC-002 |
| Aqua Purificata |
| Fagron |
| 16.00 |
| g |
| W |
| SC-001 |
| Magnesium Chloride |
| Fagron |
| 2.50 |
| g |
| W |
| SC-002 |
| MSM |
| — |
| 1.00 |
| g |
| W |
| SC-003 |
| D-Panthenol (Natural Heroes) |
| Natural Heroes |
| 1.00 |
| g |
| W |
| SC-004 |
| Vitamin E Full Spectrum |
| Natural Heroes |
| 0.50 |
| g |
| L |
| AC-006 |
| α-Bisabolol |
| — |
| 0.50 |
| g |
| L |
| BE-004 |
| Copaiba Oil |
| Aroma-Zone |
| 0.50 |
| g |
| L |
| BE-005 |
| Nymphaea caerulea (Blue Lotus) |
| — |
| 1 drop / 300 g |
| drop |
| C |
| BE-006 |
| Bacopa monnieri (Mattisson) |
| Mattisson |
| 0.50 |
| mL |
| C |
| SC-005 |
| Silicea Gel (+1 drop Silicea D8) |
| — |
| 1.00 |
| mL |
| C |
| AC-005 |
| Taurine |
| — |
| 1.00 |
| g |
| W |
| BE-011 |
| Frankincense CO₂ (Boswellia serrata) |
| — |
| 0.25 |
| mL |
| C |
| CL-001 |
| Sea Buckthorn CO₂ Colour |
| — |
| 1 |
| drop |
| C |
| CL-002 |
| Calendula CO₂ Colour |
| — |
| 1 |
| drop |
| C |
| PR-001 |
| Cosgard 221 |
| Aromantic |
| 0.70 |
| g |
| C |
3. MANUFACTURING WORKFLOW
Identical to PF-007A using the validated 10-step Lanette protocol.
4. QUALITY CONTROL
Identical SQMS Quality Control table.
5. BATCH RELEASE
Identical SQMS Batch Release table.
6. CLINICAL APPLICATION
Field
Anatomical Region
Primary Zone
Secondary Zone
Primary Target Zone
Frequency
Weeks 1–2
Week 3
Week 4
Relapse
| Value |
|---|
| T5–T9 |
| Paravertebral T5–T9 |
| Lateral costal arches |
| Epigastric (Solar Plexus) |
| 1–2× daily |
| PLEXUS-1 |
| Morning PLEXUS-2 / Evening PLEXUS-1 |
| PLEXUS-2 |
| 3 days PLEXUS-1 |
Related documents
Platform modules